Back to discover
Disease
Fever
Late-stage therapeutic developmentEmerging researchSteady momentum
9
Publications
24
Clinical trials
6
Related conditions
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2024-03-11Frontiers in immunology
Research2023-11-20Arthritis & rheumatology (Hoboken, N.J.)
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest.
Research2021-06-01The New England journal of medicine
Research2020-06-23PloS one
Research2020-03-13Military Medical Research
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Research2014-09-29The New England journal of medicine
Research2004-10-01Circulation
Identification of severe acute respiratory syndrome in Canada.
Research2003-03-31The New England journal of medicine
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Research2002-02-13Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 4 clinical trials expected to report results, the earliest in Q3 2026.
- 3 industry developments reported.
Upcoming Milestones
- Q3 2026A Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of Age
- Q1 2027Safety of Simultaneous Administration of Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody With Routine Childhood Immunizations in Infants
- Q2 2027Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries
- Q1 2030A Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Immunogenicity of 2 Doses of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Within the Routine Vaccination Schedule of Pediatric Participants ≥6 Months to <21 Months of Age
Major developments
Major trial resultsHigh impact
Results posted2026-05-13
Upcoming trial readoutHigh impact
Results expected Q1 20302026-06-29
Clinical MilestonesView all 12Hide
Results posted
Results expected
- 2026-06-29A Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Immunogenicity of 2 Doses of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Within the Routine Vaccination Schedule of Pediatric Participants ≥6 Months to <21 Months of AgeResults expected Q1 2030
- 2026-05-06A Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of AgeResults expected Q3 2026
- 2026-03-16Safety of Simultaneous Administration of Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody With Routine Childhood Immunizations in InfantsResults expected Q1 2027
- 2026-02-04Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African CountriesResults expected Q2 2027
Recently completed
- 2026-06-01Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic AreaPrimary completion
- 2026-02-28Vellore Typhoid Vaccine Impact TrialCompleted
- 2026-01-20A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 YearsCompleted
- 2025-12-31Azithromycin and Cefixime Combination Versus Azithromycin Alone for the Out-patient Treatment of Clinically Suspected or Confirmed Uncomplicated Typhoid Fever in South Asia; a Randomised Controlled TrialCompleted
- 2025-12-17A Randomized, Double-Blind, Placebo-Controlled (Participants Aged 18 to 60 Years) and Open-Label (Participants Aged 4 to 17 Years), Phase 2/3 Trial to Evaluate the Immunogenicity and Safety of 2 Doses of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healthy Adults, Adolescents, and Children in JapanCompleted
+4 more in the activity timeline below
Industry & MarketViewHide
- 2026-07-27A fever dream of jellies and slugsIndustry · Nature News
- 2026-07-27When should you treat a fever? Evolution holds the answerIndustry · Nature News
- 2026-07-22Structures and inhibition of the Crimean–Congo haemorrhagic fever virus polymeraseIndustry · Nature News
Activity timeline15
- 2027-11-30ClinicalA Prospective, Open-label, Single Arm, Multicenter, Post-authorization Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Colchicine-resistant Familial Mediterranean Fever (FMF)Withdrawn
- 2026-07-27IndustryA fever dream of jellies and slugsIndustry · Nature News
- 2026-07-27IndustryWhen should you treat a fever? Evolution holds the answerIndustry · Nature News
- 2026-07-22IndustryStructures and inhibition of the Crimean–Congo haemorrhagic fever virus polymeraseIndustry · Nature News
- 2026-06-29ClinicalA Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Immunogenicity of 2 Doses of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Within the Routine Vaccination Schedule of Pediatric Participants ≥6 Months to <21 Months of AgeResults expected Q1 2030
- 2026-06-01ClinicalYellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic AreaPrimary completion
- 2026-05-13ClinicalA Prospective, Randomized, Open-label Clinical Trial to Assess the Safety of Simultaneous Vaccination With mRNA COVID-19 Vaccine and Other Vaccines in Young Children Aged 6 Months to <5 Years.Results posted
- 2026-05-06ClinicalA Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of AgeResults expected Q3 2026
- 2026-03-16ClinicalSafety of Simultaneous Administration of Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody With Routine Childhood Immunizations in InfantsResults expected Q1 2027
- 2026-02-28ClinicalVellore Typhoid Vaccine Impact TrialCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Canakinumabapproved
Approval — Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinfla… (2009)
Anakinraapproved
Approval — Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs a… (2002)
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
17
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2009emaApproval — Canakinumab· Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: Muckle-Wells syndrome (MWS), Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). Familial Mediterranean fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate. Ilaris is also indicated for the treatment of: Still’s disease Ilaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate. Gouty arthritis Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. source ↗
2002emaApproval — Anakinra· Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone. COVID-19 Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ? 6 ng/ml. Periodic fever syndromes Kineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above: Cryopyrin-Associated Periodic Syndromes (CAPS) Kineret is indicated for the treatment of CAPS, including: Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) Muckle-Wells Syndrome (MWS) Familial Cold Autoinflammatory Syndrome (FCAS) Familial Mediterranean Fever (FMF) Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate. Still’s Disease Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20022024
Most influential
Recent publications
Major themes8
- Disease Outbreaks2
- Betacoronavirus1
- Coronary Aneurysm1
- Coronavirus Infections1
- Erythema Nodosum1
- Granulomatous Mastitis1
- Hypothermia, Induced1
- Mucocutaneous Lymph Node Syndrome1
Leading journals6
- The New England journal of medicine3
- Arthritis & rheumatology (Hoboken, N.J.)1
- Circulation1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- Frontiers in immunology1
- Military Medical Research1
Leading researchers8
- Newburger JW2
- Abed-Maillard S1
- Adachi D1
- Annborn M1
- Arance A1
- Arbyn M1
- Armstrong D1
- Awad A1
Affiliations (unnormalised)6
- Boston Children's Hospital1
- Boston Children's Hospital and Brigham and Women's Hospital1
- Breast Center1
- Bristol Medical School1
- Center for Interventional Medicine1
- Center of Infectious Disease1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Overview
Fever is an abnormal elevation of body temperature, usually occurring as part of a pathologic process. It is a clinical sign rather than a disease entity in itself, and it appears across many different conditions.
AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
An abnormal elevation of body temperature, usually as a result of a pathologic process.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.